Abstract Background: From the end of 2019 to the present, coronavirus disease 2019 (COVID-19) has put considerable pressure on the worlds medical system and caused significant mortality and economic losses around the world. In China, the Shufeng Jiedu capsule has been widely used in the treatment of COVID-19, but there is still a lack of evidence-based medical evaluation. Methods: According to the retrieval strategies, randomized controlled trials (RCTs) on the Shufeng Jiedu capsule for COVID-19 were obtained from CNKI, WanFang, VIP, PubMed, Embase and Cochrane Library, regardless of publication date, or language. Studies were screened based on inclusion and exclusion criteria, and the Cochrane risk bias assessment tool was used to evaluate the quality of the studies. The meta-analysis was performed using RevMan 5.3 and STATA 14.2 software. Ultimately, the evidentiary grade for the results will be evaluated. Results: This study will evaluate the efficacy and safety of the Shufeng Jiedu capsule in the treatment of COVID-19 and provide a more reasonable choice of medication in clinical practice. Conclusion: Our findings will provide references for future clinical decision and guidance development. Registration: INPLASY registration number: INPLASY202070024.
【저자키워드】 COVID-19, Meta-analysis, protocol, systematic review, Shufeng Jiedu capsule, 【초록키워드】 Randomized controlled trial, Treatment, coronavirus disease, Mortality, risk, China, Efficacy and safety, medication, Guidance, Clinical practice, RCTs, exclusion criteria, Cochrane Library, clinical decision, Stata, CNKI, medical system, Inclusion, was used, lack, evaluate, caused, evaluated, was performed, screened, VIP, 【제목키워드】 coronavirus disease,